

Antidepressants

Background

Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Norepinephrine Reuptake Inhibitors (SNRIs) are the most common antidepressant prescribed to treat major depressive disorder.

Side effect issues

As is with most drugs, antidepressants do not exist currently without potentially harmful side effects.
- These associated side effects may be correlated with the toxicity of medications.

Importance

Using animal models could help to screen for these potential toxic side effects before testing in humans is carried out, reducing harm and increasing benefits.

TABLE 2

Adverse effects of antidepressant drugs, based on mechanism of action

Norepinephrine transporter blockade	
Anxiety	
Augmentation of pressor effects of sympathomimetic amines	
Diaphoresis	
Tachycardia	
Tremor	
Serotonin reuptake inhibition	
Anorexia early in the treatment and weight gain later	
Dose-dependent increase or decrease in anxiety	
Ejaculatory disturbances, anorgasmia, and decreased libido	
Extrapyramidal side effects	
Interaction with monoamine oxidase inhibitors and tryptophan	
Nausea, vomiting, and diarrhea.	
Sedation or insomnia	
Serotonin syndrome	
Dopamine reuptake inhibition	
Activation and aggravation of psychosis	
Parkinsonism	
Psychomotor activation	

Khanam EA, Lamerice G, Malone DA. Side effects of antidepressants: an overview. *Cleve Clin J Med.* 2006 Apr;73(4):351-3, 356-61. doi: 10.3949/ccjm.73.4.351. PMID: 16610395.

Pharmaceutical Trials and Animal Toxicity

Animal testing has been widely used to predict efficacy and safety of pharmaceuticals in humans.


Reasons for Animal Testing

- Animal toxicity testing required by FDA since 1938
- Mice and rats share 85% analogous DNA with humans
- Animals involved in the development of vaccines, pharmaceuticals, and medical procedures

Downsides of Animal Testing

- Costs \$2-4 million per trial on average
- 88% of Preclinical trials fail
- Questionable reproducibility, reliability

Percentage of Failures of Drugs That Advance Beyond Pre-Clinical and Clinical Trials



Van Norman GA. Limitations of Animal Studies for Predicting Toxicity in Clinical Trials: Is it Time to Rethink Our Current Approach? *JACC Basic Transl Sci.* 2019;4(7):845-854. Published 2019 Nov 25. doi:10.1016/j.jbts.2019.10.008

Caenorhabditis (C.) elegans

C. elegans are transparent nematodes that are about ~1 mm in length when fully matured.

C. elegans have a rapid, observable life cycle. They are also easy to cultivate, relatively inexpensive, and non-hazardous to humans.

Pros of *C. elegans* as a Model

- 83% of proteins in *C. elegans* have homologous proteins in humans. Overall, 50% genetic similarity to humans. Serotonin transporter present as seen in humans.

Cons of *C. elegans* as a Model

- Not a whole organ species, difficult to directly translate human pathology into *C. elegans* phenotypes



Eggs, larvae, and adults of *C. elegans*


Objective and Strategies

Objective

- To determine if various antidepressants have toxic side effects on *C. elegans* through observing their development and egg laying behavior after exposure.

Strategies

- Dissolve SSRIs and SNRIs in different solvents (H₂O or ethanol)
- Expose *C. elegans* to SSRIs and SNRIs and examine if there is:
 - an increase or decrease in overall size of the nematode.
 - an increase or decrease in the total number of eggs laid per adult nematode.



Hunt et al, 2016 Journal of Applied Toxicology

Methods and Materials

Strain of worm used: N2
Fed with: *E. coli* based OP50

Day 0

- Drug plates are prepared by pipetting dilute drug solution onto small agar plates
- Worms are bleached to synchronize the population
- Bleached worms (egg-L1) are then pipetted onto the prepared drug plate

Day 1

- Seed the previously prepared drug plate with OP50
- Worms are in the L2-L3 stage

Day 2

- Four nematodes are picked from the drug plates onto regular sized plates for the later egg counts
- The remaining worms on the drug plates are anesthetized with sodium azide and measured with an eyepiece reticle on a compound microscope
- Worms are in the L4/young adult stage

Day 3


- Egg count day one. Larvae, egg, and adult nematodes are counted.

Day 4

- Egg count day two. Larvae, egg, and adult nematodes are counted.

Egg Laying and Sizing- Desipramine

A



B





Figure 1 - Toxicity of desipramine, a tricyclic antidepressant, dissolved in water. (A) Size of desipramine treated worms vs untreated (n=7). (B) Number of eggs laid (eggs + larvae) per adult after 3 days (n=7).

Egg Laying and Sizing - SNRIs (Levomilnacipran and Milnacipran)

A



B





Figure 2 - Toxicity of selective norepinephrine reuptake inhibitors dissolved in water. (A) Size of SNRI- treated worms vs untreated (n=10). (B) Number of eggs laid (eggs + larvae) per adult after 3 days (n=13).

Egg Laying and Sizing- SSRIs (Paroxetine, Citalopram, Escitalopram)

A



B




Figure 3 - Toxicity of selective serotonin reuptake inhibitors dissolved in water, and ethanol (paroxetine) (A) Size of SSRI- treated worms vs untreated (n=5-10). (B) Number of eggs laid (eggs + larvae) per adult after 3 days (n=5-10).

Conclusions and Future Directions

Conclusions

Our results indicate that:

- Desipramine showed little to no toxic effects in development, however some significance was shown when comparing the egg laying to an untreated population of nematodes.
- There was no significant difference in the size of the SNRI treated nematodes compared to untreated.
- Of the SSRIs tested, paroxetine treated worms had the most toxic developmental effects, while escitalopram treated worms exhibited the least toxic effects.

Future Directions

- Would be interesting to look at other SSRIs to see if any have a similar toxic effect as paroxetine.
- Also, would be interesting to try different types of testing on the *C. elegans*, such as swim testing.

Disclosure

All authors of this presentation have nothing to disclose concerning possible financial or personal relationships with commercial entities that may have a direct or indirect interest in the subject matter of this presentation.